Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of “Moderate Buy” from Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.3333.

A number of brokerages recently weighed in on SANA. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Bank of America reduced their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.20 on Tuesday. The stock has a 50-day simple moving average of $3.57 and a 200 day simple moving average of $3.38. Sana Biotechnology has a twelve month low of $2.61 and a twelve month high of $6.55. The stock has a market capitalization of $957.96 million, a PE ratio of -4.21 and a beta of 2.12.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, equities research analysts forecast that Sana Biotechnology will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC bought a new position in Sana Biotechnology in the 2nd quarter valued at about $54,000. WINTON GROUP Ltd purchased a new stake in Sana Biotechnology in the second quarter worth $99,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Sana Biotechnology in the second quarter valued at approximately $359,000. California State Teachers Retirement System lifted its position in shares of Sana Biotechnology by 287.8% during the second quarter. California State Teachers Retirement System now owns 634,304 shares of the company’s stock worth $2,214,000 after acquiring an additional 470,745 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Sana Biotechnology by 22.8% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 284,472 shares of the company’s stock valued at $993,000 after purchasing an additional 52,766 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company’s approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale.